NuVasive
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Revenues | 1.0b | 1.1b | 1.2b | 1.1b | 1.1b | 1.2b |
% growth | - | 7 % | 6 % | (10 %) | 8 % | 6 % |
EBITDA | 232m | 176m | 253m | 176m | 181m | 212m |
% EBITDA margin | 23 % | 16 % | 22 % | 17 % | 16 % | 18 % |
Profit | 81.6m | 12.5m | 65.2m | (37.2m) | (64.1m) | 40.4m |
% profit margin | 8 % | 1 % | 6 % | (4 %) | (6 %) | 3 % |
R&D budget | 50.4m | 61.7m | 72.4m | 79.8m | 92.6m | 98.5m |
R&D % of revenue | 5 % | 6 % | 6 % | 8 % | 8 % | 8 % |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $15.0m | Early VC | |
$9.8m | Early VC | ||
N/A | N/A | IPO | |
N/A | $40.5m | Post IPO Equity | |
* | N/A | Acquisition | |
Total Funding | $24.8m |
Recent News about NuVasive
EditNuVasive is a leading medical technology company specializing in minimally invasive spine surgery solutions. Operating in the healthcare market, NuVasive serves hospitals, surgeons, and healthcare providers by offering a comprehensive portfolio of products and services designed to improve patient outcomes and streamline surgical procedures. The company's core business model revolves around the development and commercialization of advanced surgical tools, implants, and integrated procedural solutions that facilitate less invasive spine surgeries. NuVasive generates revenue through the sale of its proprietary surgical systems, implants, and related services, as well as through ongoing support and training for healthcare professionals. By focusing on innovation and procedural efficiency, NuVasive aims to reduce surgical times, minimize patient recovery periods, and enhance overall clinical results. Key markets include North America, Europe, and Asia-Pacific, with a strong emphasis on expanding its global footprint.
Keywords: minimally invasive, spine surgery, surgical tools, implants, procedural integration, healthcare, innovation, patient outcomes, global market, medical technology.